Giannis Antetokounmpo Joins Prenetics as Shareholder in Multi-Year IM8 Partnership
Event summary
- NBA Champion Giannis Antetokounmpo becomes the first NBA athlete shareholder in a NASDAQ-listed health and longevity brand, Prenetics Global Limited.
- IM8, Prenetics' premium health and longevity brand, reached $100M ARR in just 11 months, with over 750,000 customer purchases across 31 countries.
- Antetokounmpo's 35 million followers across social platforms align with IM8’s global expansion roadmap.
- Prenetics targets $180–200 million in IM8 revenue for fiscal year 2026, with adjusted EBITDA profitability targeted by Q4 2027.
The big picture
Prenetics' partnership with Giannis Antetokounmpo underscores a strategic shift towards leveraging high-profile athlete shareholders to bolster brand credibility and market expansion. The move aligns with broader industry trends where sports figures are increasingly investing in health and wellness brands, signaling a convergence of athleticism and longevity science. With IM8’s unprecedented growth trajectory and Prenetics’ strong financial position, the partnership positions the company to capitalize on the growing demand for science-backed health solutions.
What we're watching
- Market Expansion
- How IM8 leverages Antetokounmpo’s global reach to penetrate untapped markets, particularly in Africa and Asia.
- Brand Credibility
- Whether the addition of high-profile athlete shareholders can sustain IM8’s rapid growth and differentiation in the competitive supplement industry.
- Financial Performance
- The pace at which IM8 can achieve profitability, given its current liquidity and zero-debt structure.
Related topics